APLM Apollomics Inc. IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1944885 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2024*2024-12-31 | FY2023*2023-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $0 | $0 |
| R&D expense | $24.57M | $34.19M |
| Interest expense | $179,000 | $150,000 |
| Pretax income | -$53.60M | -$172.59M |
| Income tax | $259,000 | $10,000 |
| Net income | -$53.86M | -$172.60M |
| EPS (basic) | -52.80 | -231.99 |
| EPS (diluted) | -52.80 | -231.99 |
| Weighted avg. shares (diluted) | 1.02M | 744,000 |
| Balance sheet | ||
| Cash & equivalents | $9.77M | $32.06M |
| Current assets | $10.27M | $39.92M |
| PP&E, netmay include right-of-use assets (IFRS) | $92,000 | $161,000 |
| Intangibles | $1.74M | $14.76M |
| Total assets | $13.10M | $55.39M |
| Current liabilities | $7.40M | $13.56M |
| Short-term debt | $0 | $4.24M |
| Shareholders' equity | $4.86M | $41.23M |
| Cash flow statement | ||
| Operating cash flow | -$28.74M | -$43.21M |
| Capital expenditure | $24,000 | $6,000 |
| Free cash flow | -$28.77M | -$43.22M |
| Investing cash flow | $5.98M | $21.36M |
| Financing cash flow | $468,000 | $21.23M |
| Stock-based compensation | $10.93M | $12.69M |
| Dividends paid | $0 | $0 |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.